A33 antigen specific immunoglobulin products and uses thereof
US6342587B1 · kind B1 · utility
73Cited by
16References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 22, 1999 |
| Grant date | Jan 29, 2002 |
| Priority date | — |
| Expiry date | Oct 22, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/565
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention is directed to novel CDRs and immunoglobulin products that bind to A33 antigens and methods for their use. The invention also involves a method for making humanized antibodies, using a rabbit as a host animal, and phage display library methodologies, and the antibodies themselves. The methodology is useful, for example, in generating humanized antibodies against molecules associated with cancer, such as A33, which is associated with colon cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.